Analysts expect Spark Therapeutics Inc (NASDAQ:ONCE) to report ($0.94) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Spark Therapeutics’ earnings, with estimates ranging from ($2.44) to ($0.15). Spark Therapeutics reported earnings per share of ($1.90) during the same quarter last year, which suggests a positive year over year growth rate of 50.5%. The firm is expected to issue its next quarterly earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year earnings of ($1.66) per share for the current financial year, with EPS estimates ranging from ($4.42) to $0.34. For the next fiscal year, analysts expect that the business will report earnings of ($3.70) per share, with EPS estimates ranging from ($5.35) to ($1.69). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.34). The business had revenue of $25.19 million for the quarter, compared to analysts’ expectations of $29.44 million. Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%.

ONCE has been the subject of a number of analyst reports. Credit Suisse Group increased their price objective on shares of Spark Therapeutics from $75.00 to $98.00 and gave the stock an “outperform” rating in a research note on Monday, July 9th. ValuEngine raised shares of Spark Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 2nd. Raymond James reissued a “buy” rating on shares of Spark Therapeutics in a research note on Wednesday, May 23rd. Cantor Fitzgerald set a $103.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 16th. Finally, Barclays reduced their price objective on shares of Spark Therapeutics from $85.00 to $77.00 and set an “overweight” rating for the company in a research note on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $72.15.

Large investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its position in shares of Spark Therapeutics by 90.9% during the first quarter. PNC Financial Services Group Inc. now owns 2,100 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 1,000 shares during the last quarter. Silvant Capital Management LLC bought a new position in shares of Spark Therapeutics during the first quarter worth $141,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Spark Therapeutics during the second quarter worth $203,000. Commonwealth Equity Services LLC bought a new position in shares of Spark Therapeutics during the first quarter worth $240,000. Finally, Amalgamated Bank bought a new position in shares of Spark Therapeutics during the first quarter worth $246,000.

Shares of NASDAQ ONCE traded down $0.09 during midday trading on Friday, reaching $58.95. The stock had a trading volume of 411,184 shares, compared to its average volume of 386,329. The stock has a market cap of $2.24 billion, a PE ratio of -7.73 and a beta of 2.22. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $96.59.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Story: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.